Truist cuts Ideaya Biosciences stock price target on revised estimates
Truist Securities lowered its price target on Ideaya Biosciences (IDYA) to $57 from $59, maintaining a Buy rating. The adjustment follows Q3 results and a management meeting, citing potential commercial transformation in 2027. Ideaya discontinued a phase III study to focus on higher-priority programs, saving $100M-$125M. The company has a strong financial position with a current ratio of 10.45. Multiple analysts have recently rated IDYA positively, with price targets ranging from $31 to $65.
How this was made
The 30-second read
Why it matters
The key trading takeaway is a revised valuation framework: lower darovasertib uveal melanoma revenue estimates but improved probability assumptions for DLL3, alongside a cost-saving plan to fund higher-priority programs.
Market read
This is a valuation update from one broker, with mixed signals (PT down, but probability of success up) and clear upcoming company catalysts.
What to watch
The article does not provide the magnitude of estimate changes beyond the PT, so traders may overweight the target cut versus the probability and cost-savings rationale (phase III discontinuation and $100M to $125M runway).
Background
Truist adjusted its Ideaya estimates after Q3 results and management discussion, reflecting a strategic pivot away from a phase III neoadjuvant study toward an NCCN listing path.
Ticker impact
Truist cut Ideaya Biosciences’ price target to $57 from $59 after adjusting estimates post Q3 results and a management meeting.
Likely mild downside bias as the Street digests the lower target, partially offset by the raised DLL3 probability and ongoing catalyst calendar.
The article is an analyst PT change, not a new clinical or regulatory event, but it explicitly links the revision to updated revenue/probability assumptions and upcoming R&D milestones.
Market effects
Biotech sentiment may remain selective, with investors focusing on probability-weighted success for precision oncology programs rather than near-term revenue.
Limited, as this is a single-US biotech analyst revision without broader macro/regulatory triggers.
Low, since the catalysts referenced (NCCN listing, ESMO presentations, FDA alignment) are company-specific.
Counterpoint
The PT cut may be less important than the thesis shift: Truist raised DLL3 success probability and frames major 2027 regulatory milestones, which could support re-rating if data de-risks.
Key entities
- companyIdeaya Biosciences
NASDAQ-listed biotech (IDYA) whose valuation and program probabilities were revised by Truist.
- analyst_firmTruist Securities
Issued the price target cut to $57 from $59 while maintaining a Buy rating.
- drug_candidatedarovasertib
Lead asset discussed in the uveal melanoma revenue estimate revision and potential broad label path.
- drug_candidateDLL3 ADC IDE849
Program highlighted as a higher-priority use of saved capital, with probability of success increased.
- drug_candidatePRMT5i
Mentioned as part of RAS combination therapy funded by the phase III discontinuation savings.
